The latest conference call transcript from Edwards Lifesciences Corporation has revealed a remarkable fourth quarter ...

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Keeping blood pressure under control is critical. For patients who have been unable to successfully maintain that control, there is a new, cutting-edge surgical procedure available at The Heart Center ...

JAMESTOWN — Two Sanford Health Fargo cardiology providers offer outreach services at Sanford Jamestown 2nd Ave. Clinic. Outreach services are offered on the second and fourth Wednesday of every month.

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.